GOVX
GeoVax Labs, Inc. New
stockNASDAQ
geovax labs, inc., (otcqb: govx) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our modified vaccinia ankara - virus-like particle (mva-vlp) vaccine platform. our development programs are focused on preventive vaccines against hiv, zika virus, hemorrhagic fever viruses (ebola, sudan, marburg, and lassa), and malaria, as well as therapeutic vaccines for chronic hepatitis b infections and cancers. our mva-vlp platform supports in vivo production of non-infectious vlps from the cells of the very person receiving the vaccine, mimicking a natural infection, and stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. for more information, visit www.geovax.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.28 | 2026-10-09 | -17.26% | 8.360 |
| 1M | 0.38 | 2026-09-17 | -39.30% | 1.522 |
| 3M | 0.97 | 2026-07-17 | -76.13% | 2.046 |
| 6M | 1.24 | 2026-04-17 | -81.25% | 1.958 |
| 1Y | 13.81 | 2025-10-17 | -98.32% | 1.812 |
| 2Y | 50.25 | 2024-10-17 | -99.54% | — |
| 5Y | 1,503.75 | 2021-10-18 | -99.98% | 1.398 |
GeoVax Labs, Inc. New (NASDAQ:GOVX) stock price today is $0.23, and today's volume is 146,681. GOVX is down 9.814% today. The 30 day average volume is 730,687. GOVX market cap is $2.11M with 9.09M shares outstanding.